Historic price reductions will allow millions more people to receive TB prevention, treatment and testing.

Advocates call for clarity on the terms of the Johnson & Johnson's deal with the Stop TB Partnership’s Global Drug Facility to supply generic bedaquiline.

Advocates request an urgent in-person meeting with the WHO leadership to discuss concrete actions to address technical and guideline development process-related issues previously raised.

Advocates call on WHO leadership to act immediately and correct specific technical errors in the WHO guidelines for the treatment of drug-resistant TB.

Partners In Health (PIH), Interactive Research and Development (IRD) and the Zero TB Initiative (ZTBI) welcome the release of the interim results from the STREAM Stage 1 clinical trial. This is the first clinical trial of a new treatment regimen for multidrug-resistant tuberculosis (MDR-TB), and we congratulate the investigators for successfully conducting it. Unfortunately, we have noticed much confusion about the results of this clinical trial, both in the lay press and in the countries in which we work.

The Stop TB Partnership, the Global Coalition of TB Activists (GCTA) and Partners in Health will convene the first Latin American capacity-building workshop for TB survivors on 16-18 August 2017 in Lima, Peru.

For more than a decade, Dr. KJ Seung has been working with Partners In Health to stem the spread of tuberculosis (TB), which kills more than 1 million people every year. From Peru to Lesotho, Seung, 43, has helped design, implement, and scale up programs that deliver effective treatment to patients with hard-to-treat, drug-resistant strains of TB.